Late failing heart allografts: Pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection

American Journal of Transplantation

Volumn 16, Issue 1, 2016, Pages 111-120

  Loupy, A ^a,b   Toquet, C ^c   Rouvier, P ^d   Beuscart, T ^a   Bories, M C ^a   Varnous, S ^e   Guillemain, R ^f   Pattier, S ^c   Suberbielle, C ^g   Leprince, P ^e   Lefaucheur, C ^a   Jouven, X ^a,b,f   Bruneval, P ^a,b,f   Duong Van Huyen, J P ^a,b,h  

^a Paris Translational Research Center for Organ Transplantation   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Hopital Laennec   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; ALLOANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE MEDIATED INJURY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; MULTICENTER STUDY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RETRANSPLANTATION; TIME TO TREATMENT; VASCULITIS; ADVERSE EFFECTS; ALLOGRAFT; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; GRAFT REJECTION; HEART FAILURE; PATHOLOGY; REOPERATION;

ADULT; ALLOGRAFTS; CORONARY ARTERY DISEASE; FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; ISOANTIBODIES; MALE; REOPERATION;

EID: 84956879697     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13529     Document Type: Article

References (31)

1. Lund LH, Edwards LB, Kucheryavaya AY, et al., The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report-2013; focus theme: Age. J Heart Lung Transplant 2013; 32: 951-964.
2. Terasaki PI,. Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673.
3. Racusen LC, Colvin RB, Solez K, et al., Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
4. Solez K, Colvin RB, Racusen LC, et al., Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
5. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al., Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252-269.
6. Mengel M, Sis B, Haas M, et al., Banff 2011 Meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
7. Colvin RB., Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056.
8. Lu WH, Palatnik K, Fishbein GA, et al., Diverse morphologic manifestations of cardiac allograft vasculopathy: A pathologic study of 64 allograft hearts. J Heart Lung Transplant 2011; 30: 1044-1050.
9. Angelini A, Castellani C, Fedrigo M, et al., Coronary cardiac allograft vasculopathy versus native atherosclerosis: Difficulties in classification. Virchows Arch 2014; 464: 627-635.
10. Avery RK., Cardiac-allograft vasculopathy. N Engl J Med 2003; 349: 829-830.
11. Rahmani M, Cruz RP, Granville DJ, McManus BM., Allograft vasculopathy versus atherosclerosis. Circ Res 2006; 99: 801-815.
12. Stoica SC, Cafferty F, Pauriah M, et al., The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006; 25: 420-425.
13. Caforio AL, Tona F, Fortina AB, et al., Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: Multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004; 4: 962-970.
14. CRISTAL, Agence Biomédecine. [cited 2014 Jan 1]. Available from: https://www.sipg.sante.fr/portail/.
15. Loupy A, Cazes A, Guillemain R, et al., Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant 2011; 11: 1478-1487.
16. Stewart S, Winters GL, Fishbein MC, et al., Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
17. Berry GJ, Burke MM, Andersen C, et al., The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013; 32: 1147-1162.
18. Loupy A, Lefaucheur C, Vernerey D, et al., Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
19. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N., Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation 1996; 61: 566-572.
20. Rose EA, Pepino P, Barr ML, et al., Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992; 11 (3 Pt 2): S120-S123.
21. Kfoury AG, Snow GL, Budge D, et al., A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2012; 31: 46-51.
22. Wu GW, Kobashigawa JA, Fishbein MC, et al., Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009; 28: 417-422.
23. Loupy A, Suberbielle-Boissel C, Hill GS, et al., Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
24. Hill GS, Nochy D, Bruneval P, et al., Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975-983.
25. Lefaucheur C, Loupy A, Vernerey D, et al., Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313-319.
26. Tavora F, Munivenkatappa R, Papadimitriou J, et al., Endothelitis in cardiac allograft biopsy specimens: Possible relationship to antibody-mediated rejection. J Heart Lung Transplant 2011; 30: 435-444.
27. Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM 3rd,. Antibody and complement in transplant vasculopathy. Circ Res 2007; 100: 191-203.
28. Hirohashi T, Uehara S, Chase CM, et al., Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10: 510-517.
29. Alexander RT, Lathrop S, Vollmer R, Blue L, Russell SD, Steenbergen C., Graft vascular disease after cardiac transplantation and its relationship to mean acute rejection score. Arch Pathol Lab Med 2005; 129: 1283-1287.
30. Raichlin E, Bae JH, Kushwaha SS, et al., Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol 2009; 53: 1279-1286.
31. Yamani MH, Yousufuddin M, Starling RC, et al., Does acute cellular rejection correlate with cardiac allograft vasculopathy ? J Heart Lung Transplant 2004; 23: 272-276.